Attorneys authored a 2024 Chambers Global Practice Guide chapter on “Life Sciences U.S. Trends and Developments.”
The authors provide a deep analysis of market trends that shaped the life sciences industry in 2023 and factors impacting 2024. This includes life sciences deal-making trends with smaller transactions amid shifting regulatory scrutiny and enforcement actions; increases in company divestitures, spin-outs to new companies and licensing and in-license deals for clinical and discovery stage assets.
The article also examines life sciences investments in artificial intelligence and machine learning. The authors note the growing use of AI in biologics development, driven by increasing sophistication of AI technology and algorithms, maturing computing power, increased availability of data and evolving therapeutic discovery work-flows.
The authors explain that with an improving public equity market for biotechs, and large pharmaceutical companies and venture capital funds flush with significant cash, the life sciences industry has the potential to overcome headwinds such as increased scrutiny from the Federal Trade Commission, the Inflation Reduction Act and other government actions designed to curb drug prices, as well as higher interest rates.
The chapter was authored by life sciences licensing partner David McIntosh, mergers & acquisitions partner Matt Byron and life sciences licensing associates Jenny Zhang, Ryan Kramer and Lauren Kimmel.
